Clinical Pharmacology and Drug Toxicity — MCQs

Clinical Pharmacology and Drug Toxicity Indian Medical PG Practice Questions and MCQs

Question 291: Which of the following drugs is known to cause granuloma in the liver?

A. Allopurinol (Correct Answer)
B. Nifedipine
C. Tetracycline
D. Methyl testosterone

Explanation: **Explanation:** **Correct Answer: A. Allopurinol** Drug-induced liver injury (DILI) can manifest in various histological patterns. **Allopurinol** is a classic cause of **granulomatous hepatitis**. This is a hypersensitivity reaction characterized by the formation of non-caseating granulomas in the liver parenchyma. It is often associated with the "Allopurinol Hypersensitivity Syndrome," which includes fever, rash, eosinophilia, and renal failure. **Analysis of Incorrect Options:** * **B. Nifedipine:** While calcium channel blockers can occasionally cause mild transaminitis, they are not typically associated with granuloma formation. * **C. Tetracycline:** This drug is the classic cause of **microvesicular steatosis** (fatty liver). It inhibits mitochondrial beta-oxidation of fatty acids, leading to accumulation, especially when given intravenously in high doses or during pregnancy. * **D. Methyl testosterone:** This is an anabolic steroid associated with **cholestatic jaundice** and **peliosis hepatis** (blood-filled cysts in the liver). Long-term use is also linked to hepatocellular adenomas. **High-Yield Clinical Pearls for NEET-PG:** * **Other drugs causing Hepatic Granulomas:** Phenytoin, Quinidine, Hydralazine, Sulfonamides, and Methyldopa. * **Microvesicular Steatosis:** Tetracyclines, Valproate, Salicylates (Reye’s Syndrome), and Zidovudine. * **Macrovesicular Steatosis:** Alcohol, Methotrexate, and Amiodarone. * **Centrilobular Necrosis:** Paracetamol (Acetaminophen) toxicity. * **Hepatic Angiosarcoma:** Vinyl chloride, Thorotrast, and Arsenic.

Question 292: A SLE-like syndrome is most commonly associated with the administration of which of the following drugs?

A. Rifampicin
B. Procainamide (Correct Answer)
C. Digitalis
D. Phenytoin

Explanation: **Explanation:** **Drug-Induced Lupus Erythematosus (DILE)** is a clinical syndrome that mimics Systemic Lupus Erythematosus (SLE) but occurs as a side effect of certain medications. **Why Procainamide is correct:** Procainamide (a Class IA antiarrhythmic) has the highest risk of inducing DILE, with nearly 20-30% of patients developing symptoms and up to 80% developing antinuclear antibodies (ANA) during long-term therapy. The mechanism involves the drug being metabolized by **N-acetyltransferase**. "Slow acetylators" are at a significantly higher risk because the drug remains in the body longer, leading to the formation of reactive metabolites that trigger an autoimmune response. **Why the other options are incorrect:** * **Rifampicin:** This is an antitubercular drug known for causing orange-colored secretions and hepatotoxicity, but it is not associated with SLE-like syndrome. (Note: Isoniazid, another TB drug, *is* a common cause). * **Digitalis (Digoxin):** Used in heart failure and atrial fibrillation, its toxicity presents with gastrointestinal symptoms, xanthopsia (yellow-green vision), and arrhythmias, not autoimmune syndromes. * **Phenytoin:** While phenytoin can cause various skin reactions (like SJS/TEN) and lymphadenopathy, it is a very rare cause of DILE compared to Procainamide. **NEET-PG High-Yield Pearls:** 1. **Classic Triad of DILE Drugs:** **H**ydralazine, **I**soniazid, **P**rocainamide (**HIP**). 2. **Diagnostic Marker:** **Anti-histone antibodies** are present in >95% of DILE cases (highly specific), while Anti-dsDNA (common in idiopathic SLE) is usually absent. 3. **Clinical Feature:** Unlike idiopathic SLE, DILE rarely involves the CNS or Kidneys. 4. **Management:** Symptoms typically resolve upon discontinuation of the offending drug.

Question 293: Combined phase I and II clinical trials are typically conducted for which class of drugs?

A. Antihypertensive agents
B. Anticancer drugs (Correct Answer)
C. Immunosuppressants
D. Antiarrhythmic agents

Explanation: **Explanation:** In standard clinical trials, Phase I is conducted on healthy volunteers to assess safety and pharmacokinetics. However, for **Anticancer drugs (Cytotoxic agents)**, this approach is ethically and clinically inappropriate because these drugs are often highly toxic and have significant side effects. Therefore, Phase I trials for oncology drugs are conducted directly on **patients with the target disease** (who have failed standard therapy). Because the study population already consists of patients, researchers often combine the objectives of Phase I (Maximum Tolerated Dose/Safety) and Phase II (Efficacy/Proof of Concept) into **Combined Phase I/II trials**. This accelerates the drug development process for life-threatening conditions. **Analysis of Options:** * **Antihypertensive agents (A):** These follow the traditional sequential phases (I, II, III) starting with healthy volunteers, as the drugs are generally less toxic and the condition is chronic but not immediately terminal. * **Immunosuppressants (C):** While potent, these typically undergo standard Phase I trials in healthy volunteers to establish safety profiles before moving to transplant or autoimmune patients. * **Antiarrhythmic agents (D):** These require rigorous safety testing in healthy individuals first to monitor for pro-arrhythmic effects (like QT prolongation) before testing in cardiac patients. **High-Yield NEET-PG Pearls:** * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in humans (usually <10 volunteers) to study pharmacokinetics; it does not replace Phase I. * **Phase I Exception:** Besides anticancer drugs, Phase I trials for **HIV/AIDS drugs** are also often conducted on patients rather than healthy volunteers. * **Phase IV:** Also known as **Post-Marketing Surveillance**; it is crucial for detecting rare adverse effects (e.g., Phocomelia with Thalidomide). * **Orphan Drugs:** Drugs used for rare diseases (affecting <200,000 people in the US or <1 in 1,000 in India).

Question 294: A 24-year-old farm worker is rushed to a nearby emergency department after accidental exposure to parathion. Which of the following drugs can be given to reactivate his acetylcholinesterase?

A. Atropine
B. Dimercaprol
C. Physostigmine
D. Pralidoxime (Correct Answer)

Explanation: The clinical presentation describes **Organophosphate (OP) poisoning** (parathion) [1]. Organophosphates are irreversible inhibitors of the enzyme acetylcholinesterase (AChE). They bind to the esteratic site of the enzyme via phosphorylation, leading to an accumulation of acetylcholine and a "cholinergic crisis." **Why Pralidoxime is correct:** Pralidoxime (2-PAM) is a **cholinesterase reactivator** [2,4]. It contains an oxime group that has a higher affinity for the phosphate group of the organophosphate than the enzyme itself. It pulls the phosphate group away from the enzyme, thereby regenerating active acetylcholinesterase [3]. This must be administered before **"aging"** occurs (the permanent dealkylation of the enzyme-inhibitor complex) [2,3,4]. **Why other options are incorrect:** * **Atropine:** While essential in OP poisoning, it is a **muscarinic antagonist**. It treats the symptoms (SLUDGE: Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) but does **not** reactivate the enzyme or reverse muscle paralysis (nicotinic effects). * **Dimercaprol (BAL):** This is a chelating agent used for heavy metal poisoning (Arsenic, Mercury, Lead). It has no role in cholinergic toxicity. * **Physostigmine:** This is a reversible anticholinesterase. Giving it would worsen the cholinergic crisis by further inhibiting any remaining functional AChE. It is the antidote for Atropine poisoning, not OP poisoning. **NEET-PG High-Yield Pearls:** * **Aging:** Once the enzyme-OP bond "ages," oximes are no longer effective. This is why Pralidoxime should be given within the first 24–48 hours [2,3,4]. * **Oxime Limitation:** Oximes are effective at the **Nicotinic** receptors (reversing muscle weakness/paralysis) but do not cross the Blood-Brain Barrier effectively [4]. * **Atropinization:** The goal of therapy is "Atropinization," signaled by the clearing of lung secretions and a heart rate >80 bpm (not just pupillary dilation).

Question 295: A 39-year-old carpenter develops confusion, vomiting, and blurring of vision after consuming two bottles of liquor. He has been brought to the emergency department. What should be administered?

A. Naloxone
B. Diazepam
C. Flumazenil
D. Ethyl alcohol (Correct Answer)

Explanation: ### Explanation The clinical presentation of **confusion, vomiting, and blurring of vision** ("snowstorm vision") following the consumption of illicit or adulterated liquor is classic for **Methanol poisoning**. **1. Why Ethyl Alcohol is Correct:** Methanol itself is relatively non-toxic, but it is metabolized by the enzyme **Alcohol Dehydrogenase (ADH)** into **formaldehyde** and then by aldehyde dehydrogenase into **formic acid**. Formic acid is the toxic metabolite responsible for metabolic acidosis and retinal damage (blurring of vision/blindness). * **Mechanism:** Ethyl alcohol (Ethanol) has a much higher affinity (approx. 10-20 times) for ADH than methanol. By acting as a **competitive inhibitor**, ethanol saturates the enzyme, preventing the conversion of methanol into its toxic metabolites. This allows methanol to be excreted unchanged by the kidneys. * *Note:* **Fomepizole** is the preferred modern antidote (potent ADH inhibitor), but Ethanol remains a standard treatment when Fomepizole is unavailable. **2. Why Other Options are Incorrect:** * **A. Naloxone:** An opioid antagonist used to reverse respiratory depression in opioid overdose (e.g., morphine, heroin). It has no role in alcohol toxicity. * **B. Diazepam:** A benzodiazepine used to manage alcohol *withdrawal* (delirium tremens) or seizures, but it does not treat acute methanol poisoning. * **C. Flumazenil:** A competitive benzodiazepine antagonist used to reverse benzodiazepine overdose. **3. NEET-PG High-Yield Pearls:** * **Antidote of choice:** Fomepizole (inhibits Alcohol Dehydrogenase). * **Metabolic hallmark:** High Anion Gap Metabolic Acidosis (HAGMA) with an increased Osmolar Gap. * **Specific Toxicity:** Formic acid causes "snowstorm vision" and optic disc hyperemia; it can also lead to bilateral **putaminal necrosis** (seen on MRI). * **Cofactor Therapy:** **Folic acid** (Leucovorin) is administered to enhance the breakdown of formic acid into CO₂ and water.

Question 296: All of the following are seen with sodium bicarbonate therapy EXCEPT:

A. Volume overload
B. Hypernatremia
C. Hypercalcemia (Correct Answer)
D. Activation of pyruvate carboxylase

Explanation: **Explanation:** Sodium bicarbonate ($NaHCO_3$) is a systemic alkalizing agent used in the management of metabolic acidosis and certain toxicities. **Why Hypercalcemia is the correct answer:** Sodium bicarbonate therapy causes **hypocalcemia**, not hypercalcemia. Alkalosis (increased pH) promotes the binding of free ionized calcium ($Ca^{2+}$) to serum albumin. Since only the ionized fraction is physiologically active, a rapid shift to an alkaline state leads to a decrease in ionized calcium levels, which can manifest clinically as tetany or seizures. **Analysis of incorrect options:** * **Volume Overload:** Each gram of $NaHCO_3$ contains approximately 12 mEq of sodium. This high osmotic load leads to water retention, potentially causing fluid overload, especially in patients with renal or heart failure. * **Hypernatremia:** The significant sodium content in bicarbonate therapy can lead to elevated serum sodium levels, particularly when administered as a hypertonic (8.4%) solution. * **Activation of Pyruvate Carboxylase:** Alkalosis stimulates **pyruvate carboxylase**, an enzyme that converts pyruvate to oxaloacetate. This is a key step in gluconeogenesis and helps in the utilization of lactate, which is why bicarbonate is sometimes used in specific metabolic contexts. **NEET-PG High-Yield Pearls:** * **Paradoxical CNS Acidosis:** Rapid IV bicarbonate can worsen CNS acidosis. While it raises blood pH, the resulting $CO_2$ diffuses easily across the blood-brain barrier, lowering the pH of the CSF. * **Hypokalemia:** Alkalosis causes an intracellular shift of potassium, making hypokalemia a common side effect. * **Urine Alkalinization:** It is used to enhance the excretion of acidic drugs like **salicylates** and **phenobarbital**.

Question 297: Which of the following immunosuppressive agents requires regular monitoring of renal function?

A. Azathioprine
B. Mycophenolate mofetil
C. Methotrexate
D. Cyclosporine A (Correct Answer)

Explanation: The correct answer is **Cyclosporine A**. **1. Why Cyclosporine A is correct:** Cyclosporine A is a Calcineurin Inhibitor (CNI) known for its significant **nephrotoxicity**, which is its most important dose-limiting side effect. Hypertension and renal dysfunction are the major adverse effects associated with the use of cyclosporine [2]. It causes both acute (functional) and chronic (structural) renal impairment by inducing potent vasoconstriction of the afferent arterioles. This leads to decreased renal blood flow and glomerular filtration rate (GFR). Therefore, regular monitoring of serum creatinine, urea, and blood levels (Therapeutic Drug Monitoring - TDM) is mandatory to prevent irreversible renal damage [2]. **2. Why the other options are incorrect:** * **Azathioprine:** A purine antimetabolite primarily associated with **bone marrow suppression** (leukopenia) and hepatotoxicity [1]. Its major side effect is bone marrow suppression [1]. Monitoring focuses on Complete Blood Counts (CBC) and LFTs [1]. * **Mycophenolate mofetil (MMF):** Inhibits IMDH; its main side effects are **gastrointestinal** (diarrhea, vomiting) and hematological. It is generally considered non-nephrotoxic. * **Methotrexate:** While high doses can cause crystalluria and renal failure, its primary monitoring in routine clinical use (e.g., Rheumatoid Arthritis) focuses on **hepatotoxicity** and pulmonary fibrosis. It is not a CNI and does not require the same frequency of renal monitoring as Cyclosporine. **3. NEET-PG High-Yield Pearls:** * **CNI Toxicity Profile:** Cyclosporine causes the "5 H's": **H**ypertension, **H**yperlipidemia, **H**yperglycemia, **H**irsutism, and **H**yperplasia of gums (Gingival Hyperplasia). * **Tacrolimus vs. Cyclosporine:** Both are nephrotoxic, but Tacrolimus is more likely to cause New-Onset Diabetes After Transplantation (NODAT) and neurotoxicity, while Cyclosporine causes more hirsutism and gingival hyperplasia. * **Drug Interactions:** Cyclosporine is metabolized by **CYP3A4**; inhibitors (e.g., Ketoconazole, Erythromycin) can rapidly increase levels, worsening nephrotoxicity.

Question 298: BAL is contraindicated in which of the following toxicities?

A. Arsenic toxicity
B. Lead toxicity
C. Mercury toxicity
D. Iron toxicity (Correct Answer)

Explanation: **Explanation:** **BAL (British Anti-Lewisite)**, also known as **Dimercaprol**, is a chelating agent that contains sulfhydryl groups. These groups bind to heavy metals to form stable, non-toxic, soluble chelates that are excreted in the urine. **Why Iron Toxicity is the Correct Answer:** BAL is strictly **contraindicated** in iron toxicity. When BAL binds with iron, it forms a **BAL-Iron complex** that is highly **nephrotoxic**. For iron poisoning, the specific chelator of choice is **Deferoxamine**. **Analysis of Incorrect Options:** * **A. Arsenic toxicity:** BAL is the primary chelating agent used for acute arsenic poisoning. * **B. Lead toxicity:** BAL is used in combination with Edetate calcium disodium (CaNa₂EDTA) for severe lead poisoning, especially in cases of lead encephalopathy, as it can cross the blood-brain barrier. * **C. Mercury toxicity:** BAL is effective in treating acute inorganic mercury poisoning (though it is ineffective/contraindicated for chronic organic mercury like methylmercury). **High-Yield Clinical Pearls for NEET-PG:** 1. **Route of Administration:** BAL is administered via **deep intramuscular (IM)** injection because it is dispensed in peanut oil (avoid in patients with peanut allergies). 2. **Urine pH:** BAL-metal complexes are stable in alkaline urine; hence, alkalinization of urine protects the kidneys during therapy. 3. **Specific Chelators to Remember:** * **Iron:** Deferoxamine (IV), Deferiprone (Oral), Deferasirox (Oral). * **Copper (Wilson’s Disease):** D-Penicillamine, Trientine. * **Gold/Arsenic/Mercury:** BAL. * **Lead:** Succimer (DMSA - oral chelator of choice in children), BAL, EDTA.

Question 299: The use of which of the following drugs during pregnancy can lead to Mobius syndrome?

A. Warfarin
B. Phenytoin
C. Mifepristone
D. Misoprostol (Correct Answer)

Explanation: **Explanation:** **Misoprostol** is a synthetic prostaglandin E1 (PGE1) analog. When used inappropriately as an abortifacient during the first trimester, it can cause uterine contractions leading to **vascular disruption** in the developing fetus. This ischemic event specifically affects the cranial nerve nuclei (VI and VII) and limb buds. **Mobius syndrome** is the clinical manifestation of this disruption, characterized by congenital facial paralysis (CN VII) and impaired abduction of the eyes (CN VI), often accompanied by limb defects like clubfoot or syndactyly. **Analysis of Incorrect Options:** * **Warfarin:** Exposure during the first trimester leads to **Fetal Warfarin Syndrome**, characterized by nasal hypoplasia, depressed nasal bridge, and stippled epiphyses (chondrodysplasia punctata). * **Phenytoin:** This causes **Fetal Hydantoin Syndrome**, presenting with craniofacial dysmorphism (cleft lip/palate), microcephaly, and hypoplasia of the distal phalanges and nails. * **Mifepristone:** While used alongside misoprostol for medical abortion, it is a progesterone antagonist. It is generally not associated with specific structural teratogenicity like Mobius syndrome if the pregnancy continues. **High-Yield Clinical Pearls for NEET-PG:** * **Misoprostol** is also associated with **terminal transverse limb defects**. * **Vascular Disruption Sequence:** This is the underlying mechanism for both Mobius syndrome (Misoprostol) and Gastroschisis (NSAIDs/Pseudoephedrine). * **Safe Alternatives:** For peptic ulcers in pregnancy, Sucralfate is preferred over Misoprostol due to the latter's oxytocic properties.

Question 300: Tacrolimus inhibits the transcription of which Interleukin?

A. Interleukin-1
B. Interleukin-2 (Correct Answer)
C. Interleukin-3
D. Interleukin-4

Explanation: **Explanation:** **Tacrolimus** (also known as FK506) is a potent immunosuppressant belonging to the **calcineurin inhibitor** class. **Mechanism of Action:** The primary mechanism involves binding to an intracellular protein called **FK-binding protein (FKBP)**. This Tacrolimus-FKBP complex then inhibits **calcineurin**, a calcium-dependent phosphatase. Under normal conditions, calcineurin dephosphorylates the **Nuclear Factor of Activated T-cells (NFAT)**, allowing it to enter the nucleus and promote the transcription of specific cytokines. By inhibiting calcineurin, Tacrolimus prevents the nuclear translocation of NFAT, thereby blocking the transcription of **Interleukin-2 (IL-2)**. Since IL-2 is the primary cytokine responsible for the proliferation and activation of T-lymphocytes, its inhibition leads to profound immunosuppression. **Analysis of Incorrect Options:** * **Interleukin-1 (IL-1):** Primarily produced by macrophages and monocytes; its production is more significantly affected by corticosteroids rather than calcineurin inhibitors. * **Interleukin-3 (IL-3):** A hematopoietic growth factor. While calcineurin inhibitors may have minor downstream effects on various cytokines, the hallmark and primary target is IL-2. * **Interleukin-4 (IL-4):** Involved in Th2 differentiation and B-cell switching. While Tacrolimus can reduce the expression of several early T-cell activation genes, IL-2 is the specific, high-yield target tested in clinical exams. **High-Yield Clinical Pearls for NEET-PG:** * **Comparison:** Cyclosporine also inhibits IL-2 via calcineurin inhibition but binds to **Cyclophilin** instead of FKBP. * **Potency:** Tacrolimus is roughly 10–100 times more potent than Cyclosporine. * **Side Effects:** Unlike Cyclosporine, Tacrolimus is **not** associated with gum hypertrophy or hirsutism. However, it has a higher risk of **Post-Transplant Diabetes Mellitus (PTDM)** and significant nephrotoxicity/neurotoxicity. * **Drug of Choice:** It is a mainstay in preventing organ rejection in liver and kidney transplants.

Practice by Chapter

Principles of Clinical Pharmacology

Practice Questions

Therapeutic Drug Monitoring

Practice Questions

Drug Toxicity and Overdose

Practice Questions

Antidotes and Their Applications

Practice Questions

Management of Drug Poisoning

Practice Questions

Drug-Induced Liver Injury

Practice Questions

Drug-Induced Kidney Injury

Practice Questions

Drug-Induced Blood Dyscrasias

Practice Questions

Drug-Induced QT Prolongation

Practice Questions

Pharmacovigilance

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free